Is the H0H_0 tension suggesting a 4th neutrino's generation?

Flavour oscillations experiments are suggesting the existence of a sterile, $4$th neutrino's generation with a mass of an eV order. This would mean an additional relativistic degree of freedom in the cosmic inventory, in contradiction with recent results from the Planck satellite, that have confirmed the standard value $N_{eff} \approx 3$ for the effective number of relativistic species. On the other hand, the Planck best-fit for the Hubble-Lema\^itre parameter is in tension with the local value determined with the Hubble Space Telescope, and adjusting $N_{eff}$ is a possible way to overcome such a tension. In this paper we perform a joint analysis of three complementary cosmological distance rulers, namely the CMB acoustic scale measured by Planck, the BAO scale model-independently determined by Verde {\it et al.}, and luminosity distances measured with JLA and Pantheon SNe Ia surveys. Two Gaussian priors were imposed to the analysis, the local expansion rate measured by Riess {\it et al.}, and the baryon density parameter fixed from primordial nucleosynthesis by Cooke {\it et al.}. For the sake of generality, two different models are used in the tests, the standard $\Lambda$CDM model and a generalised Chaplygin gas. The best-fit gives $N_{eff} \approx 4$ in both models, with a Chaplygin gas parameter slightly negative, $\alpha \approx -0.04$. The standard value $N_{eff} \approx 3$ is ruled out with $\approx 3\sigma$.Comment: includes some improvements in analysis, matches accepted version in PR

Directive Ultra-Wideband Planar Antennas

Two different techniques for Directive Ultra-Wideband Planar Antennas were presented throughout chapter 1: the operation of a novel bow-tie antenna with high front-to-back ratio and directivity and a differential planar UWB antenna characterized by higher gain (more than 11 dB around 7 GHz) with respect to conventional printed radiators has been demonstrated

Атаки на криптосистему RSA при помощи LLL-алгоритма: аннотация к магистерской диссертации / Илья Геннадьевич Катлинский; БГУ, Механико-математический факультет, Кафедра дифференциальных уравнений и системного анализа; науч. рук. Чергинец Д.Н.

We investigate our knowledge of early universe cosmology by exploring how much additional energy density can be placed in different components beyond those in the $\Lambda$CDM model. To do this we use a method to separate early- and late-universe information enclosed in observational data, thus markedly reducing the model-dependency of the conclusions. We find that the 95\% credibility regions for extra energy components of the early universe at recombination are: non-accelerating additional fluid density parameter $\Omega_{\rm MR} < 0.006$ and extra radiation parameterised as extra effective neutrino species $2.3 < N_{\rm eff} < 3.2$ when imposing flatness. Our constraints thus show that even when analyzing the data in this largely model-independent way, the possibility of hiding extra energy components beyond $\Lambda$CDM in the early universe is seriously constrained by current observations. We also find that the standard ruler, the sound horizon at radiation drag, can be well determined in a way that does not depend on late-time Universe assumptions, but depends strongly on early-time physics and in particular on additional components that behave like radiation. We find that the standard ruler length determined in this way is $r_{\rm s} = 147.4 \pm 0.7$ Mpc if the radiation and neutrino components are standard, but the uncertainty increases by an order of magnitude when non-standard dark radiation components are allowed, to $r_{\rm s} = 150 \pm 5$ Mpc.Comment: Submitted to JCA

Modeling of enhanced field confinement and scattering by optical wire antennas.

We describe the application of full-wave and semi-analytical numerical tools for the modeling of optical wire antennas, with the aim of providing novel guidelines for analysis and design. The concept of antenna impedance at optical frequencies is reviewed by means of finite-element simulations, whereas a surface-impedance integral equation is derived in order to perform an accurate and efficient calculation of the current distribution, and thereby to determine the equivalent-circuit parameters. These are introduced into simple circuits models, directly borrowed from radio frequency, which are applied in order to model the phenomena of enhanced field confinement at the feed gap and light scattering by optical antennas illuminated by plane waves

Observational tests for \Lambda(t)CDM cosmology

We investigate the observational viability of a class of cosmological models in which the vacuum energy density decays linearly with the Hubble parameter, resulting in a production of cold dark matter particles at late times. Similarly to the flat \Lambda CDM case, there is only one free parameter to be adjusted by the data in this class of \Lambda(t)CDM scenarios, namely, the matter density parameter. To perform our analysis we use three of the most recent SNe Ia compilation sets (Union2, SDSS and Constitution) along with the current measurements of distance to the BAO peaks at z = 0.2 and z = 0.35 and the position of the first acoustic peak of the CMB power spectrum. We show that in terms of $\chi^2$ statistics both models provide good fits to the data and similar results. A quantitative analysis discussing the differences in parameter estimation due to SNe light-curve fitting methods (SALT2 and MLCS2k2) is studied using the current SDSS and Constitution SNe Ia compilations. A matter power spectrum analysis using the 2dFGRS is also performed, providing a very good concordance with the constraints from the SDSS and Constitution MLCS2k2 data.Comment: Revised version, to appear in JCA

Clinical experience with ipilimumab 3&#160;mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP).Ipilimumab was available upon physician request for patients aged 16 or over with pretreated stage III (unresectable)/IV melanoma, for whom no other therapeutic option was available. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. Patients with stable disease or an objective response to ipilimumab were eligible for retreatment upon disease progression. Tumour assessments were conducted at baseline and week 12. Patients were monitored for adverse events (AEs) within 3 to 4 days of each scheduled visit.Of 855 patients participating in the EAP in Italy, 833 were evaluable for response. Of these, 13\% had an objective immune response, and the immune-related disease control rate was 34\%. Median progression-free survival and overall survival were 3.7 and 7.2 months, respectively. Efficacy was independent of BRAF and NRAS mutational status. Overall, 33\% of patients reported an immune-related AE (irAE). The frequency of irAEs was not associated with response to ipilimumab.Outside of a clinical trial setting, ipilimumab is a feasible treatment option in patients with pretreated metastatic melanoma, regardless of BRAF and NRAS mutational status. Data from this large cohort of patients support clinical trial evidence that ipilimumab can induce durable disease control and long-term survival in patients who have failed to respond to prior treatment

No impact of NRAS mutation on features of primary and metastatic melanoma or on outcomes of checkpoint inhibitor immunotherapy: An italian melanoma intergroup (IMI) study

Neuroblastoma RAS Viral Oncogen Homolog (NRAS) mutant melanoma is usually considered more aggressive and more responsive to checkpoint inhibitor immunotherapy (CII) than NRAS wildtype. We retrospectively recruited 331 metastatic melanoma patients treated with CII as first line: 162 NRAS-mutant/BRAF wild-type and 169 wt/wt. No substantial differences were observed among the two cohorts regarding the melanoma onset and disease-free interval. Also, overall response to CII, progression-free survival and overall survival were similar in the two groups. Therefore, our data do not show increased aggressiveness and higher responsiveness to CII in NRAS-mutant melanoma. The controversy in the published data could be due to different patient characteristics and treatment heterogeneity. We believe our data adds evidence to clear up these controversial issues. Aims: It is debated whether the NRAS-mutant melanoma is more aggressive than NRAS wildtype. It is equally controversial whether NRAS-mutant metastatic melanoma (MM) is more responsive to checkpoint inhibitor immunotherapy (CII). 331 patients treated with CII as first-line were retrospectively recruited: 162 NRAS-mutant/BRAF wild-type (mut/wt) and 169 wt/wt. We compared the two cohorts regarding the characteristics of primary and metastatic disease, disease-free interval (DFI) and outcome to CII. No substantial differences were observed between the two groups at melanoma onset, except for a more frequent ulceration in the wt/wt group (p = 0.03). Also, the DFI was very similar in the two cohorts. In advanced disease, we only found lung and brain progression more frequent in the wt/wt group. Regarding the outcomes to CII, no significant differences were reported in overall response rate (ORR), disease control rate (DCR), progression free survival (PFS) or overall survival (OS) (42% versus 37%, 60% versus 59%, 12 (95% CI, 7-18) versus 9 months (95% CI, 6-16) and 32 (95% CI, 23-49) versus 27 months (95% CI, 16-35), respectively). Irrespectively of mutational status, a longer OS was significantly associated with normal LDH, &lt;3 metastatic sites, lower white blood cell and platelet count, lower neutrophil-to-lymphocyte (N/L) ratio. Our data do not show increased aggressiveness and higher responsiveness to CII in NRAS-mutant MM

Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma

Background To evaluate the capability of basal and one-month differed white blood cells (WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to-lymphocytes ratio, NLR, and platelets-to-lymphocytes ratio, PLR) in predicting the response to immune checkpoint inhibitors (ICI) in metastatic melanoma (MM). Methods We performed a retrospective study of 272 BRAF wild-type MM patients treated with first line ICI. Bivariable analysis was used to correlate patient/tumor characteristics with clinical outcomes. Variations between time 1 and time 0 (Delta) of blood parameters were also calculated and dichotomized using cut-off values assessed by ROC curve. Results At baseline, higher neutrophils and NLR negatively correlated with PFS, OS and disease control rate (DCR). Higher PLR was also associated with worse OS. In multivariable analysis, neutrophils (p = 0.003), WBC (p = 0.069) and LDH (p = 0.07) maintained their impact on PFS, while OS was affected by LDH (p &lt; 0.001), neutrophils (p &lt; 0.001) and PLR (p = 0.022), while DCR by LDH (p = 0.03) and neutrophils (p = 0.004). In the longitudinal analysis, PFS negatively correlated with higher Delta platelets (p = 0.039), Delta WBC (p &lt; 0.001), and Delta neutrophils (p = 0.020), and with lower Delta lymphocytes (p &lt; 0.001). Moreover, higher Delta NLR and Delta PLR identified patients with worse PFS, OS and DCR. In the multivariable model, only Delta NLR influenced PFS (p = 0.004), while OS resulted affected by higher Delta WBC (p &lt; 0.001) and lower Delta lymphocytes (p = 0.038). Higher Delta WBC also affected the DCR (p = 0.003). When clustering patients in 4 categories using basal LDH and Delta NLR, normal LDH/lower Delta NLR showed a higher PFS than high LDH/higher Delta NLR (20 vs 5 months). Moreover, normal LDH/higher Delta lymphocytes had a higher OS than high LDH/lower Delta lymphocytes (50 vs. 10 months). Conclusions Baseline and early variations of blood cells, together with basal LDH, strongly predict the efficacy of ICI in MM. Our findings propose simple, inexpensive biomarkers for a better selection of patient treatments. Prospective multicenter studies are warranted to confirm these data. © 2022, The Author(s)

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel

Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous neuroendocrine carcinoma. The MCC incidence rate has rapidly grown over the last years, with Italy showing the highest increase among European countries. This malignancy has been the focus of active scientific research over the last years, focusing mainly on pathogenesis, new therapeutic trials and diagnosis. A national expert board developed 28 consensus statements that delineated the evolution of disease management and highlighted the paradigm shift towards the use of immunological strategies, which were then presented to a national MCC specialists panel for review. Sixty-five panelists answered both rounds of the questionnaire. The statements were divided into five areas: a high level of agreement was reached in the area of guidelines and multidisciplinary management, even if in real life the multidisciplinary team was not always represented by all the specialists. In the diagnostic pathway area, imaging played a crucial role in diagnosis and initial staging, planning for surgery or radiation therapy, assessment of treatment response and surveillance of recurrence and metastases. Concerning diagnosis, the usefulness of Merkel cell polyomavirus is recognized, but the agreement and consensus regarding the need for cytokeratin evaluation appears greater. Regarding the areas of clinical management and follow-up, patients with MCC require customized treatment. There was a wide dispersion of results and the suggestion to increase awareness about the adjuvant radiation therapy. The panelists unanimously agreed that the information concerning avelumab provided by the JAVELIN Merkel 200 study is adequate and reliable and that the expanded access program data could have concrete clinical implications. An immunocompromised patient with advanced MCC can be treated with immunotherapy after multidisciplinary risk/benefit assessment, as evidenced by real-world analysis and highlighted in the guidelines. A very high consensus regarding the addition of radiotherapy to treat the ongoing focal progression of immunotherapy was observed. This paper emphasizes the importance of collaboration and communication among the interprofessional team members and encourages managing patients with MCC within dedicated multidisciplinary teams. New insights in the treatment of this challenging cancer needs the contribution of many and different experts